Piribedil in Parkinson's syndrome: a clinical study.
The effect of a new dopamine receptor stimulating agent, piribedil (ET 495), was studied in 10 patients with Parkinson's syndrome, who had had no or a poor response to previous L-DOPA treatment, or had displayed marked side effects during L-DOPA administration. Piribedil produced significant improvement of the functions of activity of daily living (ADL), and appeared to have a preferential effect on parkinsonian tremor. However, treatment was difficult to control primarily because of severe psychiatric side effects.
D000203:Activities of Daily Living; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001927:Brain Diseases / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy; D009127:Muscle Rigidity / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D010879:Piperazines / Q000627:therapeutic use*; D010891:Piribedil / Q000009:adverse effects / Q000627:therapeutic use*; D000637:Transaminases / Q000097:blood; D014202:Tremor / Q000188:drug therapy
D010879:Piperazines; D010891:Piribedil; D000637:Transaminases; D000469:Alkaline Phosphatase